Ergomed plc Annual Report and Accounts 2017 Ergomed plc Annual Report and Accounts 2017 FOCUSED ON   DELIVERING GROWTH £17.4m £22.2m  Clinical Research Services:  £17.4 million, growth of 9% on PY  Drug Safety and Medical Information:  £22.2 million, growth of 68% on PY For further information, visit   We have established a portfolio of co-development partnerships  with pharmaceutical and biotech companies, using a shared  risk model, and we wholly own a pipeline of proprietary  development products for the treatment of surgical bleeding. Our offer includes clinical development, trial  management and pharmacovigilance services to  over 200 clients ranging from top 10 pharmaceutical  and generics companies to small and mid-sized  drug development companies. INTRODUCTION ERGOMED PROVIDES  SPECIALISED SERVICES  TO THE PHARMACEUTICAL  INDUSTRY . Strategic report 1 Highlights 2 At a glance 4 Company overview 10 Chairman’s statement 12 Chief Executive Officer’s review 14 Strategy 16 Strategy in action 18 Financial review 20 Principal risks Governance 22 Board of directors 24 Corporate governance statement 26 Directors’ remuneration report  (unaudited) 29 Directors’ report Financial statements 31 Independent auditor’s report 38 Consolidated income statement 39 Consolidated statement of  comprehensive income 40 Consolidated balance sheet 41 Consolidated statement of  changes in equity 42 Consolidated cash flow statement 43 Company balance sheet 44 Company statement of   changes in equity 45 Company cash flow statement 46 Notes to the financial statements Net Service Revenue 1 Ergomed plc Annual Report and Accounts 2017 Financial statements Governance Strategic report 0 5 10 15 20 25 30 35 40 45 50 2015 2016 2017 £million Net Service Revenue      Reimbursement Revenue Licence Revenue 47.6 39.2 30.2 10.2 20.0 10.0 29.2 7.6 0.4 39.6 0 10 20 30 40 50 60 70 80 90 2015 2016 2017 £million 88.0 70.0 59.0 Contracted Order Backlog £88.0 m +26% Revenue £47.6m +21% FINANCIAL HIGHLIGHTS BUSINESS HIGHLIGHTS   Acquisition of PSR Group BV (PSR), a leading contract research organisation based in The  Netherlands and focused on orphan drug development, for a total consideration of up to €5.7 million  (£5.1 million) (October 2017)   Institutional placing raising gross proceeds of £2.9 million to partially fund the initial consideration for  PSR (September 2017)   PrimeVigilance demonstrated its successful pilot project in robotic automation at an intelligent  automation seminar for the International Society of Pharmacovigilance (ISOP) (December 2017)   Board and management appointments including: Peter George, former CEO of Clinigen Group plc and  Non-Executive Director of Ergomed to Chairman; Dr Miroslav Reljanovic, founder and former CEO to  Executive Vice-Chairman; Stephen Stamp to CEO; and Jan Petracek to COO   An agreement with Allergy Therapeutics plc for a multi-study co-development partnership to support  three of Allergy Therapeutics’ OralVac products (December 2017)   First commercialisation deal for Haemostatix products with Boryung for South Korea (September  2017)   Positive Phase II data from PeproStat, our wholly-owned product and the first to come from the  Haemostatix pipeline (October 2017) Services Clinical Research Services Drug Safety and Medical Information Phases I – III Phase IV Drug Safety Medical Information Project management Patient recruitment Medical writing Data management / statistics Regulatory affairs Quality assurance Adverse event case processing Medical safety review / reports Consulting / audit Medical information QPPV / Qualified person 2 Ergomed plc Annual Report and Accounts 2017 WHAT WE DO Ergomed offers a comprehensive suite of specialised services to the pharmaceutical  industry. In our Clinical Research Services division, we undertake on behalf of  our clients all facets of clinical trial management from Phase I to IV. In our Drug  Safety and Medical Information division we provide a range of services related to  the collection, aggregation and reporting of safety issues related to drugs on the  market, sometimes called pharmacovigilance. è See pages 4 and 5 for more information Clinical Research Services Over 20 years Ergomed has built  particular expertise in oncology,  neurology, immunology and the  development of orphan drugs. Our  approach is differentiated from other  providers through our innovative  Site Management model and Study  Physician teams, resulting in a closer  and more productive relationship  between Ergomed and investigational  sites involved in clinical trials. Ergomed Clinical Research Services  operates out of 16 offices across the  Northern Hemisphere from San Antonio,  US to T aipei, T aiwan and is conducting  clinical trials in 55 countries. Comprehensive range of services AT A GLANCE è See pages 6 and 7 for more information Drug Safety and  Medical Information Through our subsidiary  PrimeVigilance, we offer the full  range of drug safety and medical  information services including adverse  event case processing, aggregate  reporting, risk management  plans, signal detection and audit..